首页> 美国卫生研究院文献>Journal of Clinical Microbiology >Combined Real-Time PCR and rpoB Gene Pyrosequencing for Rapid Identification of Mycobacterium tuberculosis and Determination of Rifampin Resistance Directly in Clinical Specimens
【2h】

Combined Real-Time PCR and rpoB Gene Pyrosequencing for Rapid Identification of Mycobacterium tuberculosis and Determination of Rifampin Resistance Directly in Clinical Specimens

机译:结合实时荧光定量PCR和rpoB基因焦磷酸测序技术快速鉴定结核分枝杆菌并直接在临床标本中测定对利福平的耐药性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Our laboratory has developed a rapid, sensitive, and specific molecular approach for detection in clinical specimens, within 48 h of receipt, of both Mycobacterium tuberculosis complex (MTBC) DNA and mutations within the 81-bp core region of the rpoB gene that are associated with rifampin (RIF) resistance. This approach, which combines an initial real-time PCR with internal inhibition assessment and a pyrosequencing assay, was validated for direct use with clinical specimens. To assess the suitability of real-time PCR for use with respiratory, nonrespiratory, acid-fast bacillus (AFB)-positive and AFB-negative specimens, we evaluated specimens received in our laboratory between 11 October 2007 and 30 June 2009. With culture used as the “gold standard,” the sensitivity, specificity, and positive and negative predictive values were determined for 1,316 specimens to be as follows: for respiratory specimens, 94.7%, 99.9%, 99.6%, and 98.6%, respectively; for nonrespiratory specimens, 88.5%, 100.0%, 100.0%, and 96.9%, respectively; for AFB-positive specimens, 99.6%, 100.0%, 100.0%, and 97.7%, respectively; and for AFB-negative specimens, 75.4%, 99.9%, 98.0%, and 98.4%, respectively. PCR inhibition was determined to be minimal in this assay, occurring in 0.2% of tests. The rpoB gene pyrosequencing assay was evaluated in a similar prospective study, in which 148 clinical specimens positive for MTBC DNA by real-time PCR were tested. The final results revealed that the results of direct testing of clinical specimens by the pyrosequencing assay were 98.6% concordant with the results of conventional testing for susceptibility to RIF in liquid culture and that our assay displayed adequate sensitivity for 96.6% of the clinical specimens tested. Used together, these assays provide reliable results that aid with the initial management of patients with suspected tuberculosis prior to the availability of the results for cultured material, and they also provide the ability to predict RIF resistance in Mycobacterium tuberculosis-positive specimens in as little as 48 h from the time of clinical specimen receipt.
机译:我们的实验室已经开发出一种快速,灵敏且特异的分子方法,可以在收到标本后48小时内检测结核分枝杆菌复合物(MTBC)DNA和rpoB基因81 bp核心区域内相关突变的临床标本具有利福平(RIF)耐药性。这种方法将初始实时PCR与内部抑制评估和焦磷酸测序分析相结合,经过验证可直接用于临床标本。为了评估实时PCR在呼吸道,非呼吸道,耐酸杆菌(AFB)阳性和AFB阴性标本中的适用性,我们评估了我们实验室在2007年10月11日至2009年6月30日期间收到的标本。作为“金标准”,确定了1,316个样本的敏感性,特异性以及阳性和阴性预测值如下:对于呼吸道样本,分别为94.7%,99.9%,99.6%和98.6%;对于非呼吸性标本,分别为88.5%,100.0%,100.0%和96.9%;对于AFB阳性标本,分别为99.6%,100.0%,100.0%和97.7%;对于AFB阴性样本,分别为75.4%,99.9%,98.0%和98.4%。在该试验中,PCR抑制被确定为最小,发生在0.2%的测试中。 rpoB基因焦磷酸测序分析是在一项类似的前瞻性研究中进行的,该研究通过实时PCR检测了148例MTBC DNA阳性的临床标本。最终结果显示,通过焦磷酸测序测定法直接检测临床标本的结果与传统方法对液体培养中RIF敏感性的检测结果相符,为98.6%,并且我们的测定法对96.6%的被检临床标本显示出足够的敏感性。结合使用,这些测定可提供可靠的结果,有助于在获得培养物结果之前对疑似结核病患者进行初步管理,并且还提供了预测结核分枝杆菌阳性样本中RIF耐药性的能力。从临床标本接收时间起48小时。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号